Selected Key Figures

  • Sales

    Key figure Sales (bar chart) Inactive key figure Sales (bar chart)
  • EBITDA Before Special Items

    Key figure EBITDA margin (bar chart) Inactive key figure EBITDA margin (bar chart)
  • Core Earnings per Share

    Inactive key figure Net income (bar chart) Key figure Net income (bar chart)

+1.2%

Following the deconsolidation of Covestro, the Bayer Group’s sales rose by 1.2% (Fx & portfolio adj.) to €8.0 billion in the third quarter of 2017.

View all Q3 key figures

+4.1%

Group EBITDA before special items increased by 4.1% to €2,204 million.

View all Q3 key figures

€1.47

Earnings per share (total) increased from €1.43 to €4.45 in the third quarter of 2017. A significant effect in this development was the remeasurement of the interest in the Covestro Group, which is mirrored in earnings from discontinued operations. Core earnings per share from continuing operations fell by 3.9% to €1.47 (Q3 2016: €1.53).

View all Q3 key figures

Business Development of the Divisions

Pharmaceuticals

Sales of Pharmaceuticals increased by 2.3 percent (Fx & portfolio adj.) to €4,065 million in the third quarter of 2017. Our key growth products Xarelto™, Eylea™, Xofigo™, Stivarga™ and Adempas™ once again delivered strong performance, with their combined sales rising by 13.2 percent (Fx adj.) to €1,522 million (Q3 2016: €1,395 million).

Find out more

Consumer Health

Sales of Consumer Health in the third quarter of 2017 fell by 2.9 percent (Fx & portfolio adj.) to €1,320 million. The decline in sales in North America was largely due to the market environment remaining challenging in the United States.

Find out more

Crop Science

Crop Science posted sales of €2,031 million in the third quarter of 2017 (Fx & portfolio adj. + 2.7 percent). Crop Protection / Seeds registered gains on a currency- and portfolio-adjusted basis that resulted particularly from gratifying development in the Asia / Pacific and North America regions.

Find out more